Cargando…

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia

The objective was to compare the clinical efficacy of cefoperazone-sulbactam with piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP). The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical outcomes were compared for patients who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Chih-Cheng, Chen, Wei-Chih, Kuo, Li-Kuo, Wang, Yao-Tung, Fu, Pin-Kuei, Ku, Shih-Chi, Fang, Wen-Feng, Chen, Chin-Ming, Tu, Chih-Yen, Cheng, Wen-Chien, Chen, Chia-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344575/
https://www.ncbi.nlm.nih.gov/pubmed/37443505
http://dx.doi.org/10.1097/MD.0000000000034284
_version_ 1785072891176419328
author Lai, Chih-Cheng
Chen, Wei-Chih
Kuo, Li-Kuo
Wang, Yao-Tung
Fu, Pin-Kuei
Ku, Shih-Chi
Fang, Wen-Feng
Chen, Chin-Ming
Tu, Chih-Yen
Cheng, Wen-Chien
Chen, Chia-Hung
author_facet Lai, Chih-Cheng
Chen, Wei-Chih
Kuo, Li-Kuo
Wang, Yao-Tung
Fu, Pin-Kuei
Ku, Shih-Chi
Fang, Wen-Feng
Chen, Chin-Ming
Tu, Chih-Yen
Cheng, Wen-Chien
Chen, Chia-Hung
author_sort Lai, Chih-Cheng
collection PubMed
description The objective was to compare the clinical efficacy of cefoperazone-sulbactam with piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP). The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical outcomes were compared for patients who received either cefoperazone-sulbactam or piperacillin-tazobactam in the treatment of SCAP. A total of 815 SCAP patients were enrolled. Among them, 343 received cefoperazone-sulbactam, and 472 received piperacillin-tazobactam. Patients who received cefoperazone-sulbactam presented with higher Charlson Comorbidity Index scores. (6.20 ± 2.77 vs 5.72 ± 2.61; P = .009). The clinical cure rates and effectiveness for patients receiving cefoperazone-sulbactam and piperacillin-tazobactam were 84.2% versus 80.3% (P = .367) and 85.4% versus 83.3% (P = .258), respectively. In addition, the overall mortality rate of the cefoperazone-sulbactam group was 16% (n = 55), which was also comparable to the piperacillin-tazobactam group (17.8%, n = 84, P = .572). The primary clinical outcomes for patients receiving cefoperazone-sulbactam were superior compared to those receiving piperacillin-tazobactam after adjusting disease severity status. The clinical efficacy of cefoperazone-sulbactam in the treatment of adult patients with SCAP is comparable to that of piperacillin-tazobactam. After adjusting for disease severity, cefoperazone-sulbactam tended to be superior to piperacillin-tazobactam.
format Online
Article
Text
id pubmed-10344575
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103445752023-07-14 The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia Lai, Chih-Cheng Chen, Wei-Chih Kuo, Li-Kuo Wang, Yao-Tung Fu, Pin-Kuei Ku, Shih-Chi Fang, Wen-Feng Chen, Chin-Ming Tu, Chih-Yen Cheng, Wen-Chien Chen, Chia-Hung Medicine (Baltimore) 6700 The objective was to compare the clinical efficacy of cefoperazone-sulbactam with piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP). The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical outcomes were compared for patients who received either cefoperazone-sulbactam or piperacillin-tazobactam in the treatment of SCAP. A total of 815 SCAP patients were enrolled. Among them, 343 received cefoperazone-sulbactam, and 472 received piperacillin-tazobactam. Patients who received cefoperazone-sulbactam presented with higher Charlson Comorbidity Index scores. (6.20 ± 2.77 vs 5.72 ± 2.61; P = .009). The clinical cure rates and effectiveness for patients receiving cefoperazone-sulbactam and piperacillin-tazobactam were 84.2% versus 80.3% (P = .367) and 85.4% versus 83.3% (P = .258), respectively. In addition, the overall mortality rate of the cefoperazone-sulbactam group was 16% (n = 55), which was also comparable to the piperacillin-tazobactam group (17.8%, n = 84, P = .572). The primary clinical outcomes for patients receiving cefoperazone-sulbactam were superior compared to those receiving piperacillin-tazobactam after adjusting disease severity status. The clinical efficacy of cefoperazone-sulbactam in the treatment of adult patients with SCAP is comparable to that of piperacillin-tazobactam. After adjusting for disease severity, cefoperazone-sulbactam tended to be superior to piperacillin-tazobactam. Lippincott Williams & Wilkins 2023-07-14 /pmc/articles/PMC10344575/ /pubmed/37443505 http://dx.doi.org/10.1097/MD.0000000000034284 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 6700
Lai, Chih-Cheng
Chen, Wei-Chih
Kuo, Li-Kuo
Wang, Yao-Tung
Fu, Pin-Kuei
Ku, Shih-Chi
Fang, Wen-Feng
Chen, Chin-Ming
Tu, Chih-Yen
Cheng, Wen-Chien
Chen, Chia-Hung
The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
title The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
title_full The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
title_fullStr The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
title_full_unstemmed The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
title_short The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
title_sort clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
topic 6700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344575/
https://www.ncbi.nlm.nih.gov/pubmed/37443505
http://dx.doi.org/10.1097/MD.0000000000034284
work_keys_str_mv AT laichihcheng theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chenweichih theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT kuolikuo theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT wangyaotung theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT fupinkuei theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT kushihchi theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT fangwenfeng theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chenchinming theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT tuchihyen theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chengwenchien theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chenchiahung theclinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT laichihcheng clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chenweichih clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT kuolikuo clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT wangyaotung clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT fupinkuei clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT kushihchi clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT fangwenfeng clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chenchinming clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT tuchihyen clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chengwenchien clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia
AT chenchiahung clinicalefficacyofcefoperazonesulbactamversuspiperacillintazobactaminthetreatmentofseverecommunityacquiredpneumonia